Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6778MR)

This product GTTS-WQ6778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4863MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ8557MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15277MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ5267MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ15092MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ2611MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ9411MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ2607MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW